24-May-2024
Benzinga (Sun, 26-May 10:44 AM ET)
Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read
Seeking Alpha News (Fri, 24-May 3:00 PM ET)
MRNA Overpriced Bull Put Spread has 52% Yield Potential
Market Chameleon (Fri, 24-May 12:22 PM ET)
TipRanks (Fri, 24-May 6:17 AM ET)
New COVID FLiRT variants spike as FDA delays key vaccine meeting
Seeking Alpha News (Thu, 23-May 2:20 PM ET)
TipRanks (Thu, 23-May 4:40 AM ET)
Pfizer, Moderna in talks with HHS over avian flu vaccine: report (update)
Seeking Alpha News (Wed, 22-May 6:09 PM ET)
Pfizer, Moderna in talks with HHS over avian flu vaccine: report
Seeking Alpha News (Wed, 22-May 6:09 PM ET)
Moderna, BioNTech close with double-digit percentage gains amid bird flu fears
Seeking Alpha News (Wed, 22-May 5:43 PM ET)
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Benzinga (Wed, 22-May 2:43 PM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of May 24, 2024, MRNA stock price climbed to $166.61 with 4,824,574 million shares trading.
MRNA has a beta of 1.69, meaning it tends to be more sensitive to market movements. MRNA has a correlation of 0.14 to the broad based SPY ETF.
MRNA has a market cap of $63.79 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $167 million in Revenue and -$3.07 earnings per share. This beat revenue expectation by $76 million and exceeded earnings estimates by $.28.
In the last 3 years, MRNA stock traded as high as $497.49 and as low as $62.55.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): QQQ, VTI, VOO, VO, SPY.
MRNA stock has underperformed the market in the last year with a return of +26.6%, while SPY returned +30.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRNA shares. However, MRNA has outperformed the market in the last 3 month and 2 week periods, returning +72.7% and +42.0%, while SPY returned +4.6% and +1.7%, respectively. This indicates MRNA has been having a stronger performance recently.
MRNA support price is $158.10 and resistance is $169.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA stock will trade within this expected range on the day.